- Home
- GIGM vs NVNO Comparison
GIGM vs NVNO Comparison
Compare GIGM & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- NVNO
- Stock Information
- Founded
- GIGM 1998
- NVNO 1987
- Country
- GIGM Taiwan
- NVNO United States
- Employees
- GIGM N/A
- NVNO N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- NVNO Medical/Dental Instruments
- Sector
- GIGM Technology
- NVNO Health Care
- Exchange
- GIGM Nasdaq
- NVNO Nasdaq
- Market Cap
- GIGM 20.2M
- NVNO 16.7M
- IPO Year
- GIGM 2000
- NVNO N/A
- Fundamental
- Price
- GIGM $1.64
- NVNO $0.94
- Analyst Decision
- GIGM
- NVNO
- Analyst Count
- GIGM 0
- NVNO 0
- Target Price
- GIGM N/A
- NVNO N/A
- AVG Volume (30 Days)
- GIGM 21.7K
- NVNO 610.4K
- Earning Date
- GIGM 10-29-2025
- NVNO 10-30-2025
- Dividend Yield
- GIGM N/A
- NVNO N/A
- EPS Growth
- GIGM N/A
- NVNO N/A
- EPS
- GIGM N/A
- NVNO N/A
- Revenue
- GIGM $3,250,000.00
- NVNO N/A
- Revenue This Year
- GIGM N/A
- NVNO N/A
- Revenue Next Year
- GIGM N/A
- NVNO N/A
- P/E Ratio
- GIGM N/A
- NVNO N/A
- Revenue Growth
- GIGM N/A
- NVNO N/A
- 52 Week Low
- GIGM $1.33
- NVNO $0.67
- 52 Week High
- GIGM $1.89
- NVNO $5.62
- Technical
- Relative Strength Index (RSI)
- GIGM 45.38
- NVNO 33.57
- Support Level
- GIGM $1.57
- NVNO $0.85
- Resistance Level
- GIGM $1.72
- NVNO $0.99
- Average True Range (ATR)
- GIGM 0.07
- NVNO 0.06
- MACD
- GIGM -0.03
- NVNO 0.10
- Stochastic Oscillator
- GIGM 24.01
- NVNO 55.83
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.